The US Federal Trade Commission’s clearance under the Hart-Scott-Rodino Anti-Trust Improvements Act is regarding the agreement between Diamyd and OMJPI for development and world-wide commercialisation of the GAD65 antigen-based therapy (Diamyd) for the treatment and prevention of type 1 diabetes and associated conditions.

In addition, Diamyd Medical has initiated clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson’s disease. The company currently has three clinical-phase products.

Diamyd Medical is a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications.

Diamyd’s advanced project is the GAD-based drug Diamyd for type 1 diabetes. Phase III trials for the drug are in progress in both Europe and the US.